Soligenix, Inc. - Common Stock (SNGX)
1.2000
-0.4200 (-25.93%)
NASDAQ · Last Trade: Sep 27th, 9:11 PM EDT
Detailed Quote
| Previous Close | 1.620 |
|---|---|
| Open | 1.190 |
| Bid | 1.190 |
| Ask | 1.210 |
| Day's Range | 1.160 - 1.290 |
| 52 Week Range | 1.090 - 6.230 |
| Volume | 6,820,282 |
| Market Cap | 4.21M |
| PE Ratio (TTM) | -0.3235 |
| EPS (TTM) | -3.7 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,207,342 |
Chart
About Soligenix, Inc. - Common Stock (SNGX)
Soligenix Inc. is a biopharmaceutical company focused on developing innovative therapies for significant unmet medical needs. The company specializes in the research and clinical development of proprietary products aimed at treating rare diseases, as well as products intended for biodefense applications. With a strong emphasis on developing treatments for conditions such as oral mucositis and acute radiation syndrome, Soligenix takes a multi-faceted approach that includes leveraging its drug development platforms and engaging in collaborations with various stakeholders to advance its pipeline. The company’s dedication to improving patient outcomes drives its commitment to delivering safe and effective therapeutic options. Read More
News & Press Releases
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.
Via Benzinga · September 26, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · September 26, 2025
Let's have a look at the gap up and gap down stocks in today's session.
Via Chartmill · September 26, 2025
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Via Chartmill · September 26, 2025
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
Via Benzinga · September 26, 2025
Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results
Soligenix (NASDAQ: SNGX) is continuing to build momentum in its mission to advance HyBryte(TM), a first-in-class treatment for early-stage cutaneous T-cell lymphoma (“CTCL”). That progress is supported by results from its pivotal FLASH trial and its ongoing FLASH 2 confirmatory study. Together, the studies highlight not only the efficacy of synthetic hypericin activated by safe fluorescent light but also the company’s broader strategy to establish HyBryte as a new standard of care in a field where therapeutic innovation has lagged ( https://www.ibn.fm/G18Hp ). With statistically significant data already achieved and confirmatory enrollment well underway, Soligenix is taking important steps toward potential regulatory approvals Worldwide.
Via Investor Brand Network · September 24, 2025
Via Benzinga · September 23, 2025
Via Benzinga · September 23, 2025
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · September 23, 2025
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson, an expert in U.S. economic and healthcare policy with extensive academic, business, and government experience, previously served as acting chairman of the White House Council of Economic Advisers and has advised FDA, CMS, and major healthcare initiatives. He currently serves as Managing Partner of MEDA Ventures and on several corporate boards. Soligenix CEO Christopher J. Schaber, PhD, said Philipson’s expertise and relationships will be instrumental as the company advances its lead product candidate HyBryte(TM) through confirmatory Phase 3 trials and toward commercialization. Dr. Philipson said he looks forward to supporting Soligenix’s mission to bring treatments for rare diseases with unmet medical needs to market.
Via Investor Brand Network · September 23, 2025
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical need. The company’s SGX942 is a novel therapeutic aimed at alleviating oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment. “Severe oral mucositis (‘SOM’) often necessitates hospitalization, opioid pain management and feeding tube placement, lowering quality of life substantially. Because of these risks, effective treatment or prevention is critical to ensuring cancer therapies remain on schedule and patients maintain nutrition and comfort,” reads a recent article. In response, the company is advancing a promising candidate, SGX942 (dusquetide), which has shown promising outcomes in clinical trials. “Soligenix is in the process of analyzing the combined phase 2 and 3 datasets to design a second pivotal phase 3 study. The company is also in the process of identifying potential partners to continue this development program.”
Via Investor Brand Network · September 19, 2025
UCLA Researchers Receive $2M Grant to Study MRI-Guided Cancer Radiation Therapy
A grant of $2 million has been awarded to UCLA Health by a for-profit company, ViewRay Systems. The purpose of this grant is to enable the university to accelerate its research efforts in finding ways in which MRI-guided radiation therapy can be leveraged to provide targeted treatment to cancer patients.
Via Investor Brand Network · September 19, 2025
Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation
Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline ( https://ibn.fm/YGu4N ). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that lack adequate treatment options while simultaneously developing critical vaccines and countermeasures for emerging infectious threats and bioterrorism risks. This combination sets the company apart as both a champion for underserved patient populations and a strategic partner in global public health preparedness.
Via Investor Brand Network · September 9, 2025
Senior NIH Officials Allege Retaliation as Motive for Their Ouster
Two former officials at the NIH have filed whistleblower complaints in which they allege that their removal from office was a result of their resistance to giving politics priority over science and their efforts to defend vaccines and research grants. They filed their complaints last week.
Via Investor Brand Network · September 9, 2025
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the publication of new data showing extended stability of its ebolavirus vaccines developed with the ThermoVax(R) platform. Bivalent and trivalent vaccines formulated from Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus antigens retained full potency after two years of storage at up to 40°C (104°F), according to a manuscript accepted by Vaccine . Developed in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa, the thermostable vaccines have demonstrated robust immune responses in animal models, with up to 100% protection in non-human primates. Soligenix noted that ThermoVax enhances protein subunit vaccines—long considered the gold standard for safety—by eliminating cold-chain requirements and improving global vaccine distribution and pandemic preparedness.
Via Investor Brand Network · September 4, 2025
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation
Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease ( https://ibn.fm/0t1aK ). This key FDA designation underscores not only the strength of recent phase 2 results but also the company’s growing reputation as a late-stage biopharmaceutical innovator dedicated to tackling serious, underserved conditions.
Via Investor Brand Network · September 4, 2025
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place Sept. 8–10, 2025. The on-demand presentation will be available beginning Sept. 5 at 7 a.m. ET through the conference platform, with Soligenix management also participating in one-on-one meetings during the event.
Via Investor Brand Network · September 2, 2025
Study Explains Why Blood Clotting is Common in IBD Patients
About 3 million people in the U.S. live with irritable bowel disease (IBD), and its prevalence is rising. Unfortunately, there isn’t a cure for the condition at the moment. Many individuals with IBD develop clots in their blood and these can result in strokes and heart attacks . Now a new study has discovered possible reasons why these clots are common and suggests a possible way to address this problem while also reducing inflammation.
Via Investor Brand Network · August 28, 2025
Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline
With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to tackle medical challenges where conventional treatments have failed to deliver meaningful solutions, recently reported on its progress so far this year ( https://ibn.fm/1dhGj ).
Via Investor Brand Network · August 26, 2025
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.
Via Benzinga · August 21, 2025
Via Benzinga · August 20, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · August 19, 2025
Via Benzinga · August 19, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · August 19, 2025
